Dr. Salvador Castaneda Vega
Scientific focus: Stroke, neuroprotective agents
Curriculum vitae and Publications
Phone: +49 7071 29 87479
Fax: +49 7071 29 4451
Stroke is a devastating disease that affects directly the lives of over 15 million people every year. It is the second cause of death in the western world still lacking an appropriate and effective treatment. Recombinant Tissue Plasminogen Activator (rTPA) is currently the only option for patients with a stroke and can be administered until 4.5 hours after the ischemic event. Time-flexible, safe and effective neuroprotective agents are therefore of primordial importance in the morbidity and mortality of stroke patients. Imaging technologies such as MR and PET, can provide great input in the study biodistribution and neuroprotection of potential therapeutic agents in vivo in animal models of disease. My main research interest is to help bring forth adequate candidates for neuroprotection through small animal experiments, which can appropriately mimic a clinical situation for adequate production of translational studies.